What's Going On With Incyte?
Incyte (INCY) today announced positive data from the Phase 3 REACH3 study, published in The New England Journal of Medicine (NEJM), showed that treatment with ruxolitinib (Jakafi) produced better outcomes in patients with steroid-refractory. Shares of the company were trading 0.01% lower to $79.86 a share.
What Does This Mean For Incyte?
Chronic GVHD is a life-threatening complication of stem cell transplants and half of patients become refractory to or dependent on first-line steroids. REACH3 data acts as the basis for the supplemental New Drug Application (sNDA) undergoing review with the U.S. Food and Drug Administration.
"Results from the REACH3 study published in NEJM are extremely compelling and underscore the potential benefits ruxolitinib can offer appropriate patients facing the serious complications associated with chronic GVHD," said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte. Adding that, "at Incyte, we remain committed to advancing our research and understanding of this complex disease, and will continue to work closely with the FDA to bring this innovative treatment to chronic GVHD patients, who currently have limited treatment options."
Incyte expects to release its second quarter financial results in August and has scheduled a conference call and webcast for 8:00 a.m. ET on Tuesday, August 3, 2021.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
INCY has a Fundamental Rank of 79. Find out what this means to you and get the rest of the rankings on INCY!
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
